Dyne Therapeutics, Inc. (DYN) reports stock transaction.
- Brian S. Posner acquired 2,500 shares on 10/02/2026.
- Posner now holds 27,000 shares directly.
- Transaction type was purchase (P).
Brian S Posner, reporting
DYN
Dyne Therapeutics, Inc. SEC filings
Every EDGAR filing for Dyne Therapeutics, Inc. (DYN), newest first, with AI summaries and stories.
- Ticker
- DYN
- CIK
- 1818794
- Sector
- Biotech and pharma
- Latest filing
- Oct 8
Next: earnings expected ~Nov 6 · 10-Q expected ~Nov 6 (deadline Nov 9)
Insider activity
- Director bought $40K
Filings
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
ROUTINE4Dyne Therapeutics, Inc.DYNLIVE ROUTINE8-KDyne Therapeutics, Inc.DYNLIVE ROUTINE144Dyne Therapeutics, Inc.DYNLIVE 2 Form 144 notices
John Cox, planned sale of DYN shares
Show all 2
- 144Planned insider sale of DYN shares
- 144Planned insider sale of DYN shares
John Cox, reporting
ROUTINE4Dyne Therapeutics, Inc.DYNLIVE 3 insider filings
Johanna Friedl-Naderer, insider filing for DYN
Show all 3
- 4Insider filing for DYN
- 4Insider filing for DYN
- 4Insider filing for DYN
Johanna Friedl-Naderer, reporting
ROUTINE144Dyne Therapeutics, Inc.DYNLIVE Douglas Kerr, planned sale of DYN shares
Douglas Kerr, reporting
ROUTINE4Dyne Therapeutics, Inc.DYNLIVE Jason P Rhodes, insider filing for DYN
Jason P Rhodes, reporting
ROUTINE4Dyne Therapeutics, Inc.DYNLIVE 4 insider filings
Johanna Friedl-Naderer, insider filing for DYN
Show all 4
- 4Insider filing for DYN
- 4Insider filing for DYN
- 4Insider filing for DYN
- 4Insider filing for DYN
Johanna Friedl-Naderer, reporting
ROUTINE144Dyne Therapeutics, Inc.DYNLIVE 3 Form 144 notices
Atlas Venture Opportunity Fund I, L.P., planned sale of DYN shares
Show all 3
- 144Planned insider sale of DYN shares
- 144Planned insider sale of DYN shares
- 144Planned insider sale of DYN shares
Atlas Venture Opportunity Fund I, L.P., reporting
ROUTINE144Dyne Therapeutics, Inc.DYNLIVE 6 Form 144 notices
Atlas Venture Opportunity Fund II, L.P., planned sale of DYN shares
Show all 6
- 144Planned insider sale of DYN shares
- 144Planned insider sale of DYN shares
- 144Planned insider sale of DYN shares
- 144Planned insider sale of DYN shares
- 144Planned insider sale of DYN shares
- 144Planned insider sale of DYN shares
Atlas Venture Opportunity Fund II, L.P., reporting
ROUTINESCHEDULE 13G/ADyne Therapeutics, Inc.DYNLIVE Ownership stake disclosure by Atlas Venture Fund XI, L.P. (amended)
Atlas Venture Fund XI, L.P., filed by
ROUTINESCHEDULE 13G/ADyne Therapeutics, Inc.DYNLIVE Ownership stake disclosure by Janus Henderson Group Ltd. (amended)
Janus Henderson Group Ltd., filed by
ROUTINESCHEDULE 13G/ADyne Therapeutics, Inc.DYNLIVE Ownership stake disclosure by FMR LLC (amended)
FMR LLC, filed by
ROUTINE8-KDyne Therapeutics, Inc.DYNLIVE ROUTINE4Dyne Therapeutics, Inc.DYNLIVE Dirk Kersten, insider filing for DYN
Dirk Kersten, reporting
NOTABLE10-QDyne Therapeutics, Inc.DYNLIVE ROUTINESCHEDULE 13G/ADyne Therapeutics, Inc.DYNLIVE Ownership stake disclosure by BlackRock, Inc. (amended)
BlackRock, Inc., filed by
ROUTINE144Dyne Therapeutics, Inc.DYNLIVE ForDyne B.V., planned sale of DYN shares
B.v. ForDyne, reporting
ROUTINE424B5Dyne Therapeutics, Inc.DYNLIVE ROUTINE8-KDyne Therapeutics, Inc.DYNLIVE ROUTINE424B5Dyne Therapeutics, Inc.DYNLIVE ROUTINE8-KDyne Therapeutics, Inc.DYNLIVE ROUTINE4Dyne Therapeutics, Inc.DYNLIVE Jason P Rhodes, insider filing for DYN
Jason P Rhodes, reporting
ROUTINE144Dyne Therapeutics, Inc.DYNLIVE 4 Form 144 notices
Atlas Venture Fund XI, L.P., planned sale of DYN shares
Show all 4
- 144Planned insider sale of DYN shares
- 144Planned insider sale of DYN shares
- 144Planned insider sale of DYN shares
- 144Planned insider sale of DYN shares
Atlas Venture Fund XI, L.P., reporting
ROUTINE144Dyne Therapeutics, Inc.DYNLIVE 3 Form 144 notices
Atlas Venture Opportunity Fund I, L.P., planned sale of DYN shares
Show all 3
- 144Planned insider sale of DYN shares
- 144Planned insider sale of DYN shares
- 144Planned insider sale of DYN shares
Atlas Venture Opportunity Fund I, L.P., reporting
ROUTINE4Dyne Therapeutics, Inc.DYNLIVE Jason P Rhodes, insider filing for DYN
Jason P Rhodes, reporting
ROUTINE144Dyne Therapeutics, Inc.DYNLIVE 3 Form 144 notices
Atlas Venture Opportunity Fund II, L.P., planned sale of DYN shares
Show all 3
- 144Planned insider sale of DYN shares
- 144Planned insider sale of DYN shares
- 144Planned insider sale of DYN shares
Atlas Venture Opportunity Fund II, L.P., reporting
ROUTINE144Dyne Therapeutics, Inc.DYNLIVE 3 Form 144 notices
Atlas Venture Fund XI, L.P., planned sale of DYN shares
Show all 3
- 144Planned insider sale of DYN shares
- 144Planned insider sale of DYN shares
- 144Planned insider sale of DYN shares
Atlas Venture Fund XI, L.P., reporting
ROUTINE4Dyne Therapeutics, Inc.DYNLIVE Erick Lucera, insider filing for DYN
Erick Lucera, reporting